Literature DB >> 12241113

Molecular cloning of the rat IL-13 alpha 2 receptor cDNA and its expression in rat tissues.

An-Hua Wu1, Walter C Low.   

Abstract

The interleukin 13 alpha 2 receptor (IL-13Ralpha2) is highly expressed in human glioma cells. As a consequence this receptor has been proposed as a potential target for immunotherapeutic approaches for treating brain tumors. In developing animal models that may utilize the IL-13Ralpha2 receptor as an immunotherapeutic target, only the murine gene sequence has thus far been elucidated. The purpose of the present study, therefore, was to determine the gene sequence and tissue distribution of IL-13Ralpha2 in the rat. A search of the NCBI expressed sequence tag (EST) database with human and mouse IL-13Ralpha2 gene sequences identified a rat EST with high homology to the human and mouse IL-13Ralpha2 conserved region. Based on the sequence information, a 1917 bp rat IL-13Ralpha2 cDNA was cloned using the 5' and 3' RACE PCR technique. The cloned rat IL-13Ralpha2 cDNA contains a full-length 1158 bp open reading frame. The deduced protein is 91.2% and 54.2% homologous to mouse and human IL- 13Ralpha2, respectively, at the amino acid level. Analysis shows that the rat IL-13Ralpha2 is structurally conserved and similar to human and mouse. It has a very short cytoplasmic domain, an extracellular domain containing an N-terminal fibronectin type III domain, four putative N-glycosylation sites, and a growth factor and cytokine receptor family motif WSEWS. Using RT-PCR techniques, the mRNA of rat IL-13Ralpha2 was detected in rat brain, spleen, liver, thymus, stomach, testis, and three rat glioblastoma cell lines C6, A15A5 and 9L. The cloning of rat IL-13Ralpha2 may be helpful to establish a rat model for IL-13Ralpha2 related glioma therapies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12241113     DOI: 10.1023/a:1019690120307

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

1.  Chromosome mapping and expression of the human interleukin-13 receptor.

Authors:  J Guo; F Apiou; M P Mellerin; B Lebeau; Y Jacques; S Minvielle
Journal:  Genomics       Date:  1997-05-15       Impact factor: 5.736

2.  Expression of interleukin 13 receptor in glioma and renal cell carcinoma: IL13Ralpha2 as a decoy receptor for IL13.

Authors:  J Bernard; D Treton; C Vermot-Desroches; C Boden; P Horellou; E Angevin; P Galanaud; J Wijdenes; Y Richard
Journal:  Lab Invest       Date:  2001-09       Impact factor: 5.662

3.  The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway.

Authors:  K Kawakami; J Taguchi; T Murata; R K Puri
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

4.  Characterization and comparison of the interleukin 13 receptor with the interleukin 4 receptor on several cell types.

Authors:  N Vita; S Lefort; P Laurent; D Caput; P Ferrara
Journal:  J Biol Chem       Date:  1995-02-24       Impact factor: 5.157

5.  Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen.

Authors:  W Debinski; D M Gibo
Journal:  Mol Med       Date:  2000-05       Impact factor: 6.354

6.  Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: non-neoplastic glia and low-grade astrocytoma differ from malignant glioma.

Authors:  H Liu; B S Jacobs; J Liu; R A Prayson; M L Estes; G H Barnett; B P Barna
Journal:  Cancer Immunol Immunother       Date:  2000-08       Impact factor: 6.968

7.  Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain.

Authors:  D Caput; P Laurent; M Kaghad; J M Lelias; S Lefort; N Vita; P Ferrara
Journal:  J Biol Chem       Date:  1996-07-12       Impact factor: 5.157

8.  Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function.

Authors:  A N McKenzie; J A Culpepper; R de Waal Malefyt; F Brière; J Punnonen; G Aversa; A Sato; W Dang; B G Cocks; S Menon
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

9.  Interleukin-13 receptor as a unique target for anti-glioblastoma therapy.

Authors:  S R Husain; B H Joshi; R K Puri
Journal:  Int J Cancer       Date:  2001-04-15       Impact factor: 7.316

10.  Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.

Authors:  K Kawakami; M Kawakami; B H Joshi; R K Puri
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 13.312

View more
  2 in total

1.  Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.

Authors:  Cory Allen; Georgia Paraskevakou; Ianko Iankov; Caterina Giannini; Mark Schroeder; Jann Sarkaria; Mark Schroeder; Raj K Puri; Stephen J Russell; Evanthia Galanis
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

2.  Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model.

Authors:  Brad J Stish; Seunguk Oh; Daniel A Vallera
Journal:  J Neurooncol       Date:  2007-12-15       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.